These compounds might indirectly support NAD+ levels by protecting cells from oxidative damage and preserving existing NAD+ stores
This will lead to faster progression of chronic kidney disease (CKD)
Adding glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism alongside GLP-1R creates a genuinely different metabolic research profile not just an incremental improvement
They create a biological window of opportunity
This product combines 250 mg of -Nicotinamide Adenine Dinucleotide (NAD) with 250 mg of CurcuWIN, a highly bioavailable turmeric extract standardized to curcuminoids
For all other agents including albiglutide, dulaglutide, efpeglenatide, exenatide, liraglutide, and semaglutide, tirzepatide showed no statistically significant differences in MACE risk